Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation

Digestive Diseases and Sciences

Volumn 57, Issue 9, 2012, Pages 2248-2266

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; De novo; Post transplantation; Recurrence

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE T1 ANTIBODY; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIVER KIDNEY MICROSOME TYPE 1 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SERINE TRANSFER RNA; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ACUTE GRAFT REJECTION; ACUTE HEPATITIS; AUTOIMMUNE HEPATITIS; CHOLESTASIS; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DE NOVO AUTOIMMUNE HEPATITIS; DENDRITIC CELL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GRAFT FAILURE; GRAFT RECIPIENT; GROUPS BY AGE; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGAMMAGLOBULINEMIA; HYPERGLYCEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER NECROSIS; LIVER TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MEMORY T LYMPHOCYTE; MOLECULAR MIMICRY; NONHUMAN; ORGAN DONOR; POSTTRANSPLANT AUTOIMMUNE HEPATITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT AUTOIMMUNE HEPATITIS; RECURRENT DISEASE; RETRANSPLANTATION; REVIEW; RISK FACTOR; ROSETTE FORMATION; SCORING SYSTEM; SURVIVAL; TREATMENT OUTCOME; VIRUS INFECTION;

GRAFT REJECTION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84866384808     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2179-3     Document Type: Review

References (232)

1. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113-128.
2. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2007;53:43-78. (Pubitemid 46978249)
3. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58-72.
4. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991;13:701-706.
5. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028-2035. (Pubitemid 27240790)
6. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317-323. (Pubitemid 27069049)
7. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31:49-53. (Pubitemid 30033688)
8. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227-235. (Pubitemid 46696944)
9. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379-388.
10. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851-856. (Pubitemid 29458270)
11. Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645-652. (Pubitemid 29409251)
12. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225-232. (Pubitemid 32677377)
13. Gregorio GV, Choudhuri K, Ma Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol. 2003;133:404-413. (Pubitemid 37046966)
14. Bogdanos DP, Lenzi M, Okamoto M, et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol. 2004;17:83-92. (Pubitemid 39572192)
15. Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol Immunol. 2004;40:1113-1120. (Pubitemid 38221193)
16. Bowen DG. Of mice and molecular mimicry: modeling autoimmune hepatitis. Hepatology. 2008;48:1013-1015.
17. Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol. 1998;161:3527-3535.
18. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 2002;8:505-513. (Pubitemid 34619081)
19. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transpl Surg. 1995;1:109-115.
20. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl. 2001;7:285-291. (Pubitemid 32331530)
21. Kerkar N, Hadzic N, Davies ET, et al. De novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409-413. (Pubitemid 28064165)
22. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51:313-333. (Pubitemid 43010443)
23. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315-330.
24. Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689-700.
25. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866-871. (Pubitemid 24374156)
26. Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625-631. (Pubitemid 38834047)
27. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology. 1999;30:1374-1380.
28. Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302-308. (Pubitemid 34969945)
29. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532-538.
30. Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15:2314-2328.
31. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360-365. (Pubitemid 28363659)
32. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34:659-665. (Pubitemid 32927988)
33. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int. 2004;24:322-329. (Pubitemid 39162072)
34. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263-270. (Pubitemid 36546352)
35. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol. 2004;28:471-478. (Pubitemid 38436520)
36. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246-249. (Pubitemid 43344883)
37. Sempoux C, Horsmans Y, Lerut J, Rahier J, Geubel A. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver. 1997;17:311-315. (Pubitemid 28014681)
38. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001;7:302-310. (Pubitemid 32331533)
39. Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation. Ann Gastroenterol Hepatol. 2010;1:79-89.
40. Jones DE, James OF, Portmann B, et al. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology. 1999;30:53-57. (Pubitemid 29300568)
41. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology. 2001;34:464-470. (Pubitemid 32791325)
42. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation. 2001;71:664-668. (Pubitemid 32268071)
43. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006;44:489-501. (Pubitemid 44214890)
44. Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl. 2008;14:750-755. (Pubitemid 351895504)
45. Fiel MI, Agarwal K, Stanca C, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 2008;14:861-871. (Pubitemid 351895516)
46. Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl. 2008;14:625-632. (Pubitemid 351696273)
47. Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008;14:1281-1286.
48. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation. 1984;37:363-365. (Pubitemid 14105426)
49. Wright HL, Bou-Abboud CF, Hassanein T, et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation. 1992;53:136-139.
50. Birnbaum AH, Benkov KJ, Pittman NS, et al. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr. 1997;25:20-25. (Pubitemid 27284280)
51. Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation. 1998;66:1645-1650. (Pubitemid 29034985)
52. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68:253-256. (Pubitemid 29360286)
53. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999;30:131-141. (Pubitemid 29023662)
54. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002;8:519-526. (Pubitemid 34619083)
55. Yusoff IF, House AK, De Boer WB, et al. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol. 2002;17:203-207. (Pubitemid 34415675)
56. Duclos-Vallee JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut. 2003;52:893-897. (Pubitemid 36613499)
57. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transpl. 2004;18:62-69. (Pubitemid 38195546)
58. Duclos-Vallee JC. Recurrence of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation. Acta Gastroenterol Belg. 2005;68:331-336.
59. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12:1813-1824. (Pubitemid 44911808)
60. Montano-Loza AJ, Mason AL, Ma M, et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15:1254-1261.
61. Yao H, Michitaka K, Tokumoto Y, et al. Recurrence of autoimmune hepatitis after liver transplantation without elevation of alanine aminotransferase. World J Gastroenterol. 2007;13:1618-1621. (Pubitemid 46672675)
62. Hytiroglou P, Gutierrez JA, Freni M, et al. Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: a blind histologic study. Hepatol Res. 2009;39:577-584.
63. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology. 2000;32:185-192. (Pubitemid 30614649)
64. Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl Surg. 1999;5:375-380. (Pubitemid 29437014)
65. Junge G, Neuhaus R, Schewior L, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc. 2005;37:1695-1696. (Pubitemid 40790799)
66. Hayashi M, Keeffe EB, Krams SM, et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg. 1998;4:208-214. (Pubitemid 28225647)
67. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis. 2002;22:379-386. (Pubitemid 35379506)
68. Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin Liver Dis. 2000;20:481-495. (Pubitemid 32048438)
69. Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl. 2009;15:931-938.
70. Li KK, Neuberger J. Recurrent nonviral liver disease following liver transplantation. Expert Rev Gastroenterol Hepatol. 2009;3:257-268.
71. Rosenthal P, Emond JC, Heyman MB, et al. Pathological changes in yearly protocol liver biopsy specimens from healthy pediatric liver recipients. Liver Transpl Surg. 1997;3:559-562. (Pubitemid 27498466)
72. Mells G, Neuberger J. Protocol liver allograft biopsies. Transplantation. 2008;85:1686-1692.
73. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl. 2001;7:790-796. (Pubitemid 32851300)
74. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938. (Pubitemid 29514229)
75. Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.
76. Duclos-Vallee JC, Yilmaz F, Johanet C, et al. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transpl. 2005;19:591-599. (Pubitemid 41341689)
77. Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421-3438.
78. O'Grady JG. Phenotypic expression of recurrent disease after liver transplantation. Am J Transpl. 2010;10:1149-1154.
79. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation. 2001;72:267-272. (Pubitemid 32729347)
80. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992;103:1290-1295.
81. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol. 2000;33:163-166. (Pubitemid 30418950)
82. Lohse AW, Obermayer-Straub P, Gerken G, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's diseasepossible association with a steroid-resistant transplant rejection episode. J Hepatol. 1999;31:149-155. (Pubitemid 29287621)
83. Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology. 1993;18:998-1005.
84. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176. (Pubitemid 351975541)
85. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540-1548.
86. Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009;50:538-545.
87. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997;63:243-249. (Pubitemid 27121206)
88. Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid-dependent after liver transplantation? Liver Transpl Surg. 1999;5:460-463. (Pubitemid 29437027)
89. Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transpl Proc. 2007;39:1166-1170. (Pubitemid 46764831)
90. Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation: a disease continuum or a fresh start? Liver Transpl. 2009;15:1169-1171.
91. Nunez-Martinez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. Transpl Proc. 2003;35:1857-1858. (Pubitemid 37093740)
92. Hess AD, Fischer AC. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation. 1989;48:895-900. (Pubitemid 20018337)
93. Hess AD, Fischer AC, Horwitz LR, Laulis MK. Cyclosporine-induced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression. Transpl Proc. 1993;25:2811-2813. (Pubitemid 23314248)
94. Hess AD, Horwitz LR, Laulis MK. Cyclosporine-induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo. Transpl Proc. 1993;25:1218-1221. (Pubitemid 23078963)
95. Hess AD, Horwitz LR, Laulis MK, Fuchs E. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin Immunol Immunopathol. 1993;69:341-350.
96. Gotz G, Neuhaus R, Bechstein WO, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transpl Proc. 1999;31:430-431. (Pubitemid 29127513)
97. Cooper MH, Hartman GG, Starzl TE, Fung JJ. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. Transpl Proc. 1991;23:3234-3235.
98. Hess DA, O'Leary EF, Lee JT, et al. Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole. FASEB J. 2001;15:1855-1857.
99. Beschorner WE, Suresch DL, Shinozawa T, Santos GW, Hess AD. Thymic immunopathology after cyclosporine: effect of irradiation and age on medullary involution and recovery. Transpl Proc. 1988;20:1072-1078.
100. Lotem J, Kama R, Sachs L. Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin. Proc Natl Acad Sci USA. 1999;96:12016-12020. (Pubitemid 29502850)
101. Wang HG, Pathan N, Ethell IM, et al. Ca2 + -induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339-343. (Pubitemid 129523456)
102. Bucy RP, Xu XY, Li J, Huang G. Cyclosporin A-induced autoimmune disease in mice. J Immunol. 1993;151:1039-1050. (Pubitemid 23215769)
103. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med. 1983;158:1-8. (Pubitemid 13073506)
104. Ahmed M, Mutimer D, Hathaway M, et al. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transpl Proc. 1997;29:496. (Pubitemid 27123503)
105. Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology. 2000;32:693-700.
106. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 2000;174:250-259. (Pubitemid 30201393)
107. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215-221.
108. Devlin J, Donaldson P, Portmann B, et al. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl Surg. 1995;1:162-165.
109. Neumann UP, Guckelberger O, Langrehr JM, et al. Impact of human leukocyte antigen matching in liver transplantation. Transplantation. 2003;75:132-137. (Pubitemid 36139709)
110. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol. 2003;170:1481-1489. (Pubitemid 36139518)
111. Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J Autoimmun. 2010;34:38-44.
112. Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183-1187.
113. Huppertz HI, Treichel U, Gassel AM, Jeschke R. Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol. 1995;23:204-208.
114. Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409-1422. (Pubitemid 351831496)
115. Christen U, Holdener M, Hintermann E. Cytochrome P450 2D6 as a model antigen. Dig Dis. 2010;28:80-85.
116. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991;88:1370-1378.
117. Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science. 1998;279:1344-1347. (Pubitemid 28119574)
118. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci. 2002;47:2139-2150. (Pubitemid 35205286)
119. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology. 1992;103:1041-1047.
120. Yoshizawa K, Ota M, Katsuyama Y, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol. 2005;42:578-584. (Pubitemid 40342939)
121. Qiu DK, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol. 2003;18:63-67. (Pubitemid 36062589)
122. Vazquez-Garcia MN, Alaez C, Olivo A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol. 1998;28:985-990. (Pubitemid 28275977)
123. Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146-150. (Pubitemid 24332760)
124. Bittencourt PL, Goldberg AC, Cancado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906-1913. (Pubitemid 29315909)
125. Goldberg AC, Bittencourt PL, Mougin B, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol. 2001;62:165-169. (Pubitemid 32171655)
126. Djilali-Saiah I, Fakhfakh A, Louafi H, et al. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol. 2006;45:844-850. (Pubitemid 44646681)
127. Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322-1329. (Pubitemid 40904356)
128. Fan LY, Tu XQ, Zhu Y, et al. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol. 2005;11:2768-2772. (Pubitemid 40704245)
129. Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol. 2005;20:249-255. (Pubitemid 40343277)
130. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35:126-131. (Pubitemid 34032552)
131. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997;26:1054-1066. (Pubitemid 27415802)
132. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643-649. (Pubitemid 29106772)
133. Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology. 2001;34:494-501. (Pubitemid 32786639)
134. Renous R, Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. Characterization of the antigenicity of the formiminotransferase-cyclodeaminase in type 2 autoimmune hepatitis. Exp Cell Res. 2004;292:332-341. (Pubitemid 38018849)
135. McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol. 1984;55:347-354. (Pubitemid 14223472)
136. Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis. 1991;11:215-222.
137. Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol. 2000;121:364-374. (Pubitemid 30659778)
138. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun. 2010;34:59-65.
139. Vierling JM. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg. 1999;5:S1-S20.
140. Gray D, Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature. 1988;336:70-73. (Pubitemid 18262136)
141. Sprent J. Lifespans of naive, memory and effector lymphocytes. Curr Opin Immunol. 1993;5:433-438. (Pubitemid 23197458)
142. McLean AR, Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA. 1995;92:3707-3711.
143. Umeki S, Kusunoki Y, Cologne JB, et al. Lifespan of human memory T-cells in the absence of T-cell receptor expression. Immunol Lett. 1998;62:99-104. (Pubitemid 28332934)
144. Obhrai JS, Oberbarnscheidt MH, Hand TW, et al. Effector T cell differentiation and memory T cell maintenance outside secondary lymphoid organs. J Immunol. 2006;176:4051-4058. (Pubitemid 44264383)
145. Bell EB, Westermann J. CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol. 2008;29:405-411.
146. Aguilera I, Sousa JM, Gavilan F, et al. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl. 2004;10:1166-1172. (Pubitemid 39255364)
147. Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci. 2010;55:1761-1769.
148. Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Liver Transpl. 2001;7:S99-S108.
149. Rowe IA, Webb K, Gunson BK, et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int. 2008;21:459-465. (Pubitemid 351490169)
150. Cattan P, Berney T, Conti F, et al. Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int. 2002;15:34-38. (Pubitemid 36055897)
151. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269-291.
152. Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol. 2012;10:346-353.
153. Czaja AJ, Wang KK, Shiels MT, Katzmann JA. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J Hepatol. 1993;17:180-186. (Pubitemid 23054484)
154. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10:81-90; discussion 91-82. (Pubitemid 26341300)
155. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol. 2000;109:16-22.
156. Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod Asp Immunobiol. 2001;2:78-82.
157. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Design. 2011;17:3120-3140.
158. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890-897. (Pubitemid 34258384)
159. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685-689. (Pubitemid 13007694)
160. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis. 2009;29:286-296.
161. Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int. 2009;22:144-152.
162. Rumbo C, Shneider BL, Emre SH. Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. Pediatr Transpl. 2004;8:571-575. (Pubitemid 40052355)
163. Hurtova M, Duclos-Vallee JC, Johanet C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl. 2001;7:556-558. (Pubitemid 32547275)
164. Hasenbein W, Albani J, Englert C, et al. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Pediatr Transpl. 2006;10:938-942. (Pubitemid 44683640)
165. Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. Liver injury from cyclosporine A. Dig Dis Sci. 1990;35:693-697. (Pubitemid 20207370)
166. Kowdley KV, Keeffe EB. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am. 1995;24:991-1001. (Pubitemid 26107539)
167. Emre S, Genyk Y, Schluger LK, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int (Off J Eur Soc Organ Transpl). 2000;13:73-78. (Pubitemid 30417387)
168. Taniai N, Akimaru K, Ishikawa Y, et al. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nihon Med Sch. 2008;75:187-191. (Pubitemid 351845554)
169. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118. (Pubitemid 30394534)
170. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723-727. (Pubitemid 41038652)
171. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799-802. (Pubitemid 47031057)
172. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:1036-1040.
173. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54:2519-2522.
174. Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588-592.
175. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol. 2004;18:321-326. (Pubitemid 38801788)
176. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819-825. (Pubitemid 41361901)
177. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063-3070.
178. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009;51:156-160.
179. Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009;51:8-10.
180. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335-343.
181. Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Expert Rev Gastroenterol Hepatol. 2011;5:517-522.
182. Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation. 2003;76:130-136. (Pubitemid 36877126)
183. Czaja AJ. Autoimmune hepatitis: focusing on therapies other than steroids. Can J Gastroenterol (accepted for publication).
184. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transpl. 2005;5:1085-1089. (Pubitemid 40571258)
185. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756-758. (Pubitemid 24225367)
186. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-1945. (Pubitemid 39071573)
187. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-484. (Pubitemid 43199434)
188. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation. 2006;81:445-454. (Pubitemid 43255733)
189. Hernandez HM, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr. 2001;32:131-136. (Pubitemid 32280624)
190. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol. 2001;126:535-539. (Pubitemid 34008729)
191. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation. 2004;78:128-135. (Pubitemid 39099420)
192. Gibelli NE, Tannuri U, Mello ES, et al. Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation. Pediatr Transpl. 2006;10:371-376.
193. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transpl. 2007;7:955-963. (Pubitemid 46481195)
194. Eguchi S, Takatsuki M, Hidaka M, et al. De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease. J Gastroenterol Hepatol. 2008;23:e165-e169. (Pubitemid 352019437)
195. Cho JM, Kim KM, Oh SH, et al. De novo autoimmune hepatitis in Korean children after liver transplantation: a single institution's experience. Transpl Proc. 2011;43:2394-2396.
196. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology. 2006;43:1109-1117. (Pubitemid 43724635)
197. Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl. 2009;15:530-539.
198. Guido M, Burra P. De novo autoimmune hepatitis after liver transplantation. Semin Liver Dis. 2011;31:71-81.
199. Tan CK, Sian Ho JM. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. Liver Transpl. 2001;7:461-465. (Pubitemid 32492586)
200. Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transpl Proc. 2006;38:1467-1470.
201. Yoshizawa K, Shirakawa H, Ichijo T, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transpl. 2008;22:385-390. (Pubitemid 351689672)
202. Zhang Y, Wang B, Wang T. De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis: a case report. Transpl Proc. 2010;42:3854-3857.
203. Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci. 2001;46:140-147. (Pubitemid 32221849)
204. McNally RJ, James PW, Ducker S, James OF. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology. 2011;54:2099-2103.
205. Richter A, Grabhorn E, Helmke K, et al. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transpl. 2007;21:427-432. (Pubitemid 46711410)
206. Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.
207. Tamaro G, Sonzogni A, Torre G. Monitoring de novo autoimmune hepatitis (LKM positive) by serum type-IV collagen after liver transplant: a paediatric case. Clin Chim Acta. 2001;310:25-29. (Pubitemid 32727312)
208. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002;35:349-356. (Pubitemid 34106374)
209. Huguet S, Vinh J, Johanet C, et al. Identification by proteomic tool of atypical anti-liver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. Ann NY Acad Sci. 2007;1109:345-357. (Pubitemid 47511378)
210. Aguilera I, Sousa JM, Gavilan F, et al. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transpl Proc. 2005;37:3968-3969. (Pubitemid 43015226)
211. Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr. 2007;45:222-227. (Pubitemid 47220531)
212. Aguilera I, Sousa JM, Praena JM, Gomez-Bravo MA, Nunez-Roldan A. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. Clin Transpl. 2011;25:207-212.
213. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224-1231. (Pubitemid 32319165)
214. Inui A, Sogo T, Komatsu H, Miyakawa H, Fujisawa T. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. Liver Transpl. 2005;11:504-507. (Pubitemid 40704061)
215. Mieli-Vergani G, Vergani D. Autoimmune liver diseases in childrenwhat is different from adulthood? Best Pract Res Clin Gastroenterol. 2011;25:783-795.
216. Gibelli NE, Tannuri U, Pinho-Apezzato ML, et al. Sirolimus in pediatric liver transplantation: a single-center experience. Transpl Proc. 2009;41:901-903.
217. Pappo O, Ramos H, Starzl TE, Fung JJ, Demetris AJ. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol. 1995;19:192-206.
218. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638-645. (Pubitemid 28405409)
219. Lefkowitch JH. Diagnostic issues in liver transplantation pathology. Clin Liver Dis. 2002;6:555-570. (Pubitemid 34755905)
220. Quiroga J, Colina I, Demetris AJ, Starzl TE, Van Thiel DH. Cause and timing of first allograft failure in orthotopic liver transplantation: a study of 177 consecutive patients. Hepatology. 1991;14:1054-1062.
221. Blakolmer K, Jain A, Ruppert K, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000;69:2330-2336. (Pubitemid 30408998)
222. Freese DK, Snover DC, Sharp HL, et al. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology. 1991;13:882-891.
223. Lowes JR, Hubscher SG, Neuberger JM. Chronic rejection of the liver allograft. Gastroenterol Clin North Am. 1993;22:401-420. (Pubitemid 23194297)
224. Demetris AJ, Seaberg EC, Batts KP, et al. Chronic liver allograft rejection: a National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the reliability of current criteria and proposal of an expanded definition. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Am J Surg Pathol. 1998;22:28-39. (Pubitemid 28016749)
225. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31:792-799. (Pubitemid 30118655)
226. Backman L, Gibbs J, Levy M, et al. Causes of late graft loss after liver transplantation. Transplantation. 1993;55:1078-1082. (Pubitemid 23150739)
227. Tsamandas AC, Jain AB, Felekouras ES, et al. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997;64:252-257. (Pubitemid 27332668)
228. Herzog D, Soglio DB, Fournet JC, et al. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl. 2008;14:946-955. (Pubitemid 352003893)
229. Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 2007;13:966-974. (Pubitemid 47163188)
230. Ludwig J, Gross JB Jr, Perkins JD, Moore SB. Persistent centrilobular necroses in hepatic allografts. Hum Pathol. 1990;21:656-661. (Pubitemid 20204955)
231. Khettry U, Backer A, Ayata G, et al. Centrilobular histopathologic changes in liver transplant biopsies. Hum Pathol. 2002;33:270-276. (Pubitemid 34461459)
232. Krasinskas AM, Ruchelli ED, Rand EB, Chittams JL, Furth EE. Central venulitis in pediatric liver allografts. Hepatology. 2001;33:1141-1147. (Pubitemid 32378213)